Effectiveness of eribulin as first-line or second-line chemotherapy for HER2-negative hormone-resistant advanced or metastatic breast cancer: findings from the multi-institutional, prospective, observational KBCRN A001: E-SPEC study
Background The optimal positioning of eribulin treatment remains unclear. This study aimed to investigate the effectiveness of eribulin administration as first- and second-line chemotherapy in patients with endocrine-resistant advanced or metastatic breast cancer (AMBC) in the real-world clinical se...
Gespeichert in:
| Veröffentlicht in: | Breast cancer (Tokyo, Japan) Japan), 2022-09, Vol.29 (5), p.796-807 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 807 |
|---|---|
| container_issue | 5 |
| container_start_page | 796 |
| container_title | Breast cancer (Tokyo, Japan) |
| container_volume | 29 |
| creator | Kikawa, Yuichiro Kotake, Takeshi Tsuyuki, Shigeru Kang, Yookija Takahara, Sachiko Fujimoto, Yuri Yamashiro, Hiroyasu Yoshibayashi, Hiroshi Takada, Masahiro Yasuoka, Rie Nakatsukasa, Katsuhiko Yamagami, Kazuhiko Suwa, Hirofumi Okuno, Toshitaka Nakayama, Ichiro Kato, Tatsushi Ogura, Nobuko Moriguchi, Yoshio Ishiguro, Hiroshi Kagimura, Tatsuo Taguchi, Tetsuya Sugie, Tomoharu Toi, Masakazu |
| description | Background
The optimal positioning of eribulin treatment remains unclear. This study aimed to investigate the effectiveness of eribulin administration as first- and second-line chemotherapy in patients with endocrine-resistant advanced or metastatic breast cancer (AMBC) in the real-world clinical setting.
Methods
This multi-institutional prospective cohort study enrolled patients with triple-negative AMBC or estrogen receptor-positive AMBC refractory to at least one previous endocrine therapy. The overall survival (OS) from the start of first-line (OS1) and second-line chemotherapy (OS2) was assessed. Data analysis included real-world chemotherapy sequences of first- to third-line chemotherapy regimens. The adjusted hazard ratio (HR) with 95% confidence interval (CI) for treatment regimen comparison was calculated using a stratified proportional hazards model.
Results
Among 201 patients enrolled, 180 were included in the final analysis. Eribulin was administered as first- and second-line chemotherapy to 46 (26.6%) and 70 (47.9%) patients, respectively. Median OS1 and OS2 were 2.25 (95% CI 1.07–2.68) and 1.75 (95% CI, 1.28–2.45) years for first- and second-line eribulin, respectively. Oral 5-FU followed by eribulin had a numerically longer OS1 (2.84 years) than the other sequences. Among patients who proceeded to second-line or later chemotherapy, the median OS1 for those treated with anthracycline or taxane as first- or second-line (
n
= 98) was 2.56 years (95% CI 2.27–2.74), while it was 2.87 years (95% CI 2.20–4.32) for those who avoided anthracycline and taxane as first- and second-line (
n
= 48) (adjusted HR, 1.20; 95% CI 0.70–2.06). In the exploratory analysis, OS1 was 2.55 (95% CI 2.14–2.75) and 2.91 years (95% CI 2.61–4.32) for those aged |
| doi_str_mv | 10.1007/s12282-022-01357-x |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2654298045</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A714262896</galeid><sourcerecordid>A714262896</sourcerecordid><originalsourceid>FETCH-LOGICAL-c504t-8898f75c04c070c610efb139423a32e4df75b7a8cbe4cdf319bf5deb2491163d3</originalsourceid><addsrcrecordid>eNp9Ul1rFDEUHUSxtfoHfJCALz40NV_z1bd1Ga1YVKo-h0zmZjdlJlmTzNL9x_4Ms04VBJEQknvPuSeXm1MUzym5oITUryNlrGGYsLwpL2t896A4pU1DsGCcP8x3Lgiumqo5KZ7EeEuI4DWpHhcnvBQVIVV1WvzojAGd7B4cxIi8QRBsP4_WIRWRsSEmnANAPqAI2rthCfUWJp-2ENTugEwGr7obhh1s1FELbX2YvAMcINqYlEtIDXvlNAxHoQmSytlkNeoD5CvSRyxc5gfdYN0mvxz8hLI-muYxWWxdTDbNyXqnxnO0Cz7ulrbPke8jhL1aMPThzfrmI1oRQi9Rh7987tYopnk4PC0eGTVGeHZ_nhXf3nZf11f4-tO79-vVNdYlEQk3TduYutREaFITXVECpqe8zRNVnIEYMtjXqtE9CD0YTtvelAP0TLSUVnzgZ8WrRTf3-H2GmORko4ZxVA78HCWrSsHahogyU18u1I0aQVpnfApKH-lyVVPBKta0VWZd_IOV1wCTzR8Cxub8XwVsKdB5SjGAkbtgJxUOkhJ5NI5cjCOzceQv48i7XPTivu25n2D4U_LbKZnAF0LMkNtAkLd-Dnni8X-yPwEg59I7</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2654298045</pqid></control><display><type>article</type><title>Effectiveness of eribulin as first-line or second-line chemotherapy for HER2-negative hormone-resistant advanced or metastatic breast cancer: findings from the multi-institutional, prospective, observational KBCRN A001: E-SPEC study</title><source>SpringerLink Journals - AutoHoldings</source><creator>Kikawa, Yuichiro ; Kotake, Takeshi ; Tsuyuki, Shigeru ; Kang, Yookija ; Takahara, Sachiko ; Fujimoto, Yuri ; Yamashiro, Hiroyasu ; Yoshibayashi, Hiroshi ; Takada, Masahiro ; Yasuoka, Rie ; Nakatsukasa, Katsuhiko ; Yamagami, Kazuhiko ; Suwa, Hirofumi ; Okuno, Toshitaka ; Nakayama, Ichiro ; Kato, Tatsushi ; Ogura, Nobuko ; Moriguchi, Yoshio ; Ishiguro, Hiroshi ; Kagimura, Tatsuo ; Taguchi, Tetsuya ; Sugie, Tomoharu ; Toi, Masakazu</creator><creatorcontrib>Kikawa, Yuichiro ; Kotake, Takeshi ; Tsuyuki, Shigeru ; Kang, Yookija ; Takahara, Sachiko ; Fujimoto, Yuri ; Yamashiro, Hiroyasu ; Yoshibayashi, Hiroshi ; Takada, Masahiro ; Yasuoka, Rie ; Nakatsukasa, Katsuhiko ; Yamagami, Kazuhiko ; Suwa, Hirofumi ; Okuno, Toshitaka ; Nakayama, Ichiro ; Kato, Tatsushi ; Ogura, Nobuko ; Moriguchi, Yoshio ; Ishiguro, Hiroshi ; Kagimura, Tatsuo ; Taguchi, Tetsuya ; Sugie, Tomoharu ; Toi, Masakazu</creatorcontrib><description>Background
The optimal positioning of eribulin treatment remains unclear. This study aimed to investigate the effectiveness of eribulin administration as first- and second-line chemotherapy in patients with endocrine-resistant advanced or metastatic breast cancer (AMBC) in the real-world clinical setting.
Methods
This multi-institutional prospective cohort study enrolled patients with triple-negative AMBC or estrogen receptor-positive AMBC refractory to at least one previous endocrine therapy. The overall survival (OS) from the start of first-line (OS1) and second-line chemotherapy (OS2) was assessed. Data analysis included real-world chemotherapy sequences of first- to third-line chemotherapy regimens. The adjusted hazard ratio (HR) with 95% confidence interval (CI) for treatment regimen comparison was calculated using a stratified proportional hazards model.
Results
Among 201 patients enrolled, 180 were included in the final analysis. Eribulin was administered as first- and second-line chemotherapy to 46 (26.6%) and 70 (47.9%) patients, respectively. Median OS1 and OS2 were 2.25 (95% CI 1.07–2.68) and 1.75 (95% CI, 1.28–2.45) years for first- and second-line eribulin, respectively. Oral 5-FU followed by eribulin had a numerically longer OS1 (2.84 years) than the other sequences. Among patients who proceeded to second-line or later chemotherapy, the median OS1 for those treated with anthracycline or taxane as first- or second-line (
n
= 98) was 2.56 years (95% CI 2.27–2.74), while it was 2.87 years (95% CI 2.20–4.32) for those who avoided anthracycline and taxane as first- and second-line (
n
= 48) (adjusted HR, 1.20; 95% CI 0.70–2.06). In the exploratory analysis, OS1 was 2.55 (95% CI 2.14–2.75) and 2.91 years (95% CI 2.61–4.32) for those aged < 65 and ≥ 65 years, respectively (adjusted HR of ≥ 65, 0.91; 95% CI 0.56–1.46).
Conclusions
Eribulin or oral 5-FU administration in first- and second-line chemotherapy without anthracycline/taxane was acceptable in the real-world setting.
Trial registration
This study is registered with Clinical Trials.gov (NCT 02,551,263).</description><identifier>ISSN: 1340-6868</identifier><identifier>EISSN: 1880-4233</identifier><identifier>DOI: 10.1007/s12282-022-01357-x</identifier><identifier>PMID: 35460066</identifier><language>eng</language><publisher>Singapore: Springer Nature Singapore</publisher><subject>Analysis ; Anthracyclines ; Breast cancer ; Cancer ; Cancer Research ; Chemotherapy ; Estrogen ; Information management ; Medical research ; Medicine ; Medicine & Public Health ; Medicine, Experimental ; Metastasis ; Oncology ; Original Article ; Surgery ; Surgical Oncology</subject><ispartof>Breast cancer (Tokyo, Japan), 2022-09, Vol.29 (5), p.796-807</ispartof><rights>The Author(s), under exclusive licence to The Japanese Breast Cancer Society 2022</rights><rights>2022. The Author(s), under exclusive licence to The Japanese Breast Cancer Society.</rights><rights>COPYRIGHT 2022 Springer</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c504t-8898f75c04c070c610efb139423a32e4df75b7a8cbe4cdf319bf5deb2491163d3</citedby><cites>FETCH-LOGICAL-c504t-8898f75c04c070c610efb139423a32e4df75b7a8cbe4cdf319bf5deb2491163d3</cites><orcidid>0000-0002-3852-5991</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12282-022-01357-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12282-022-01357-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35460066$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kikawa, Yuichiro</creatorcontrib><creatorcontrib>Kotake, Takeshi</creatorcontrib><creatorcontrib>Tsuyuki, Shigeru</creatorcontrib><creatorcontrib>Kang, Yookija</creatorcontrib><creatorcontrib>Takahara, Sachiko</creatorcontrib><creatorcontrib>Fujimoto, Yuri</creatorcontrib><creatorcontrib>Yamashiro, Hiroyasu</creatorcontrib><creatorcontrib>Yoshibayashi, Hiroshi</creatorcontrib><creatorcontrib>Takada, Masahiro</creatorcontrib><creatorcontrib>Yasuoka, Rie</creatorcontrib><creatorcontrib>Nakatsukasa, Katsuhiko</creatorcontrib><creatorcontrib>Yamagami, Kazuhiko</creatorcontrib><creatorcontrib>Suwa, Hirofumi</creatorcontrib><creatorcontrib>Okuno, Toshitaka</creatorcontrib><creatorcontrib>Nakayama, Ichiro</creatorcontrib><creatorcontrib>Kato, Tatsushi</creatorcontrib><creatorcontrib>Ogura, Nobuko</creatorcontrib><creatorcontrib>Moriguchi, Yoshio</creatorcontrib><creatorcontrib>Ishiguro, Hiroshi</creatorcontrib><creatorcontrib>Kagimura, Tatsuo</creatorcontrib><creatorcontrib>Taguchi, Tetsuya</creatorcontrib><creatorcontrib>Sugie, Tomoharu</creatorcontrib><creatorcontrib>Toi, Masakazu</creatorcontrib><title>Effectiveness of eribulin as first-line or second-line chemotherapy for HER2-negative hormone-resistant advanced or metastatic breast cancer: findings from the multi-institutional, prospective, observational KBCRN A001: E-SPEC study</title><title>Breast cancer (Tokyo, Japan)</title><addtitle>Breast Cancer</addtitle><addtitle>Breast Cancer</addtitle><description>Background
The optimal positioning of eribulin treatment remains unclear. This study aimed to investigate the effectiveness of eribulin administration as first- and second-line chemotherapy in patients with endocrine-resistant advanced or metastatic breast cancer (AMBC) in the real-world clinical setting.
Methods
This multi-institutional prospective cohort study enrolled patients with triple-negative AMBC or estrogen receptor-positive AMBC refractory to at least one previous endocrine therapy. The overall survival (OS) from the start of first-line (OS1) and second-line chemotherapy (OS2) was assessed. Data analysis included real-world chemotherapy sequences of first- to third-line chemotherapy regimens. The adjusted hazard ratio (HR) with 95% confidence interval (CI) for treatment regimen comparison was calculated using a stratified proportional hazards model.
Results
Among 201 patients enrolled, 180 were included in the final analysis. Eribulin was administered as first- and second-line chemotherapy to 46 (26.6%) and 70 (47.9%) patients, respectively. Median OS1 and OS2 were 2.25 (95% CI 1.07–2.68) and 1.75 (95% CI, 1.28–2.45) years for first- and second-line eribulin, respectively. Oral 5-FU followed by eribulin had a numerically longer OS1 (2.84 years) than the other sequences. Among patients who proceeded to second-line or later chemotherapy, the median OS1 for those treated with anthracycline or taxane as first- or second-line (
n
= 98) was 2.56 years (95% CI 2.27–2.74), while it was 2.87 years (95% CI 2.20–4.32) for those who avoided anthracycline and taxane as first- and second-line (
n
= 48) (adjusted HR, 1.20; 95% CI 0.70–2.06). In the exploratory analysis, OS1 was 2.55 (95% CI 2.14–2.75) and 2.91 years (95% CI 2.61–4.32) for those aged < 65 and ≥ 65 years, respectively (adjusted HR of ≥ 65, 0.91; 95% CI 0.56–1.46).
Conclusions
Eribulin or oral 5-FU administration in first- and second-line chemotherapy without anthracycline/taxane was acceptable in the real-world setting.
Trial registration
This study is registered with Clinical Trials.gov (NCT 02,551,263).</description><subject>Analysis</subject><subject>Anthracyclines</subject><subject>Breast cancer</subject><subject>Cancer</subject><subject>Cancer Research</subject><subject>Chemotherapy</subject><subject>Estrogen</subject><subject>Information management</subject><subject>Medical research</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Medicine, Experimental</subject><subject>Metastasis</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Surgery</subject><subject>Surgical Oncology</subject><issn>1340-6868</issn><issn>1880-4233</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9Ul1rFDEUHUSxtfoHfJCALz40NV_z1bd1Ga1YVKo-h0zmZjdlJlmTzNL9x_4Ms04VBJEQknvPuSeXm1MUzym5oITUryNlrGGYsLwpL2t896A4pU1DsGCcP8x3Lgiumqo5KZ7EeEuI4DWpHhcnvBQVIVV1WvzojAGd7B4cxIi8QRBsP4_WIRWRsSEmnANAPqAI2rthCfUWJp-2ENTugEwGr7obhh1s1FELbX2YvAMcINqYlEtIDXvlNAxHoQmSytlkNeoD5CvSRyxc5gfdYN0mvxz8hLI-muYxWWxdTDbNyXqnxnO0Cz7ulrbPke8jhL1aMPThzfrmI1oRQi9Rh7987tYopnk4PC0eGTVGeHZ_nhXf3nZf11f4-tO79-vVNdYlEQk3TduYutREaFITXVECpqe8zRNVnIEYMtjXqtE9CD0YTtvelAP0TLSUVnzgZ8WrRTf3-H2GmORko4ZxVA78HCWrSsHahogyU18u1I0aQVpnfApKH-lyVVPBKta0VWZd_IOV1wCTzR8Cxub8XwVsKdB5SjGAkbtgJxUOkhJ5NI5cjCOzceQv48i7XPTivu25n2D4U_LbKZnAF0LMkNtAkLd-Dnni8X-yPwEg59I7</recordid><startdate>20220901</startdate><enddate>20220901</enddate><creator>Kikawa, Yuichiro</creator><creator>Kotake, Takeshi</creator><creator>Tsuyuki, Shigeru</creator><creator>Kang, Yookija</creator><creator>Takahara, Sachiko</creator><creator>Fujimoto, Yuri</creator><creator>Yamashiro, Hiroyasu</creator><creator>Yoshibayashi, Hiroshi</creator><creator>Takada, Masahiro</creator><creator>Yasuoka, Rie</creator><creator>Nakatsukasa, Katsuhiko</creator><creator>Yamagami, Kazuhiko</creator><creator>Suwa, Hirofumi</creator><creator>Okuno, Toshitaka</creator><creator>Nakayama, Ichiro</creator><creator>Kato, Tatsushi</creator><creator>Ogura, Nobuko</creator><creator>Moriguchi, Yoshio</creator><creator>Ishiguro, Hiroshi</creator><creator>Kagimura, Tatsuo</creator><creator>Taguchi, Tetsuya</creator><creator>Sugie, Tomoharu</creator><creator>Toi, Masakazu</creator><general>Springer Nature Singapore</general><general>Springer</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3852-5991</orcidid></search><sort><creationdate>20220901</creationdate><title>Effectiveness of eribulin as first-line or second-line chemotherapy for HER2-negative hormone-resistant advanced or metastatic breast cancer: findings from the multi-institutional, prospective, observational KBCRN A001: E-SPEC study</title><author>Kikawa, Yuichiro ; Kotake, Takeshi ; Tsuyuki, Shigeru ; Kang, Yookija ; Takahara, Sachiko ; Fujimoto, Yuri ; Yamashiro, Hiroyasu ; Yoshibayashi, Hiroshi ; Takada, Masahiro ; Yasuoka, Rie ; Nakatsukasa, Katsuhiko ; Yamagami, Kazuhiko ; Suwa, Hirofumi ; Okuno, Toshitaka ; Nakayama, Ichiro ; Kato, Tatsushi ; Ogura, Nobuko ; Moriguchi, Yoshio ; Ishiguro, Hiroshi ; Kagimura, Tatsuo ; Taguchi, Tetsuya ; Sugie, Tomoharu ; Toi, Masakazu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c504t-8898f75c04c070c610efb139423a32e4df75b7a8cbe4cdf319bf5deb2491163d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Analysis</topic><topic>Anthracyclines</topic><topic>Breast cancer</topic><topic>Cancer</topic><topic>Cancer Research</topic><topic>Chemotherapy</topic><topic>Estrogen</topic><topic>Information management</topic><topic>Medical research</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Medicine, Experimental</topic><topic>Metastasis</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Surgery</topic><topic>Surgical Oncology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kikawa, Yuichiro</creatorcontrib><creatorcontrib>Kotake, Takeshi</creatorcontrib><creatorcontrib>Tsuyuki, Shigeru</creatorcontrib><creatorcontrib>Kang, Yookija</creatorcontrib><creatorcontrib>Takahara, Sachiko</creatorcontrib><creatorcontrib>Fujimoto, Yuri</creatorcontrib><creatorcontrib>Yamashiro, Hiroyasu</creatorcontrib><creatorcontrib>Yoshibayashi, Hiroshi</creatorcontrib><creatorcontrib>Takada, Masahiro</creatorcontrib><creatorcontrib>Yasuoka, Rie</creatorcontrib><creatorcontrib>Nakatsukasa, Katsuhiko</creatorcontrib><creatorcontrib>Yamagami, Kazuhiko</creatorcontrib><creatorcontrib>Suwa, Hirofumi</creatorcontrib><creatorcontrib>Okuno, Toshitaka</creatorcontrib><creatorcontrib>Nakayama, Ichiro</creatorcontrib><creatorcontrib>Kato, Tatsushi</creatorcontrib><creatorcontrib>Ogura, Nobuko</creatorcontrib><creatorcontrib>Moriguchi, Yoshio</creatorcontrib><creatorcontrib>Ishiguro, Hiroshi</creatorcontrib><creatorcontrib>Kagimura, Tatsuo</creatorcontrib><creatorcontrib>Taguchi, Tetsuya</creatorcontrib><creatorcontrib>Sugie, Tomoharu</creatorcontrib><creatorcontrib>Toi, Masakazu</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Breast cancer (Tokyo, Japan)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kikawa, Yuichiro</au><au>Kotake, Takeshi</au><au>Tsuyuki, Shigeru</au><au>Kang, Yookija</au><au>Takahara, Sachiko</au><au>Fujimoto, Yuri</au><au>Yamashiro, Hiroyasu</au><au>Yoshibayashi, Hiroshi</au><au>Takada, Masahiro</au><au>Yasuoka, Rie</au><au>Nakatsukasa, Katsuhiko</au><au>Yamagami, Kazuhiko</au><au>Suwa, Hirofumi</au><au>Okuno, Toshitaka</au><au>Nakayama, Ichiro</au><au>Kato, Tatsushi</au><au>Ogura, Nobuko</au><au>Moriguchi, Yoshio</au><au>Ishiguro, Hiroshi</au><au>Kagimura, Tatsuo</au><au>Taguchi, Tetsuya</au><au>Sugie, Tomoharu</au><au>Toi, Masakazu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effectiveness of eribulin as first-line or second-line chemotherapy for HER2-negative hormone-resistant advanced or metastatic breast cancer: findings from the multi-institutional, prospective, observational KBCRN A001: E-SPEC study</atitle><jtitle>Breast cancer (Tokyo, Japan)</jtitle><stitle>Breast Cancer</stitle><addtitle>Breast Cancer</addtitle><date>2022-09-01</date><risdate>2022</risdate><volume>29</volume><issue>5</issue><spage>796</spage><epage>807</epage><pages>796-807</pages><issn>1340-6868</issn><eissn>1880-4233</eissn><abstract>Background
The optimal positioning of eribulin treatment remains unclear. This study aimed to investigate the effectiveness of eribulin administration as first- and second-line chemotherapy in patients with endocrine-resistant advanced or metastatic breast cancer (AMBC) in the real-world clinical setting.
Methods
This multi-institutional prospective cohort study enrolled patients with triple-negative AMBC or estrogen receptor-positive AMBC refractory to at least one previous endocrine therapy. The overall survival (OS) from the start of first-line (OS1) and second-line chemotherapy (OS2) was assessed. Data analysis included real-world chemotherapy sequences of first- to third-line chemotherapy regimens. The adjusted hazard ratio (HR) with 95% confidence interval (CI) for treatment regimen comparison was calculated using a stratified proportional hazards model.
Results
Among 201 patients enrolled, 180 were included in the final analysis. Eribulin was administered as first- and second-line chemotherapy to 46 (26.6%) and 70 (47.9%) patients, respectively. Median OS1 and OS2 were 2.25 (95% CI 1.07–2.68) and 1.75 (95% CI, 1.28–2.45) years for first- and second-line eribulin, respectively. Oral 5-FU followed by eribulin had a numerically longer OS1 (2.84 years) than the other sequences. Among patients who proceeded to second-line or later chemotherapy, the median OS1 for those treated with anthracycline or taxane as first- or second-line (
n
= 98) was 2.56 years (95% CI 2.27–2.74), while it was 2.87 years (95% CI 2.20–4.32) for those who avoided anthracycline and taxane as first- and second-line (
n
= 48) (adjusted HR, 1.20; 95% CI 0.70–2.06). In the exploratory analysis, OS1 was 2.55 (95% CI 2.14–2.75) and 2.91 years (95% CI 2.61–4.32) for those aged < 65 and ≥ 65 years, respectively (adjusted HR of ≥ 65, 0.91; 95% CI 0.56–1.46).
Conclusions
Eribulin or oral 5-FU administration in first- and second-line chemotherapy without anthracycline/taxane was acceptable in the real-world setting.
Trial registration
This study is registered with Clinical Trials.gov (NCT 02,551,263).</abstract><cop>Singapore</cop><pub>Springer Nature Singapore</pub><pmid>35460066</pmid><doi>10.1007/s12282-022-01357-x</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-3852-5991</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1340-6868 |
| ispartof | Breast cancer (Tokyo, Japan), 2022-09, Vol.29 (5), p.796-807 |
| issn | 1340-6868 1880-4233 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2654298045 |
| source | SpringerLink Journals - AutoHoldings |
| subjects | Analysis Anthracyclines Breast cancer Cancer Cancer Research Chemotherapy Estrogen Information management Medical research Medicine Medicine & Public Health Medicine, Experimental Metastasis Oncology Original Article Surgery Surgical Oncology |
| title | Effectiveness of eribulin as first-line or second-line chemotherapy for HER2-negative hormone-resistant advanced or metastatic breast cancer: findings from the multi-institutional, prospective, observational KBCRN A001: E-SPEC study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T21%3A17%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effectiveness%20of%20eribulin%20as%20first-line%20or%20second-line%20chemotherapy%20for%20HER2-negative%20hormone-resistant%20advanced%20or%20metastatic%20breast%20cancer:%20findings%20from%20the%20multi-institutional,%20prospective,%20observational%20KBCRN%20A001:%20E-SPEC%20study&rft.jtitle=Breast%20cancer%20(Tokyo,%20Japan)&rft.au=Kikawa,%20Yuichiro&rft.date=2022-09-01&rft.volume=29&rft.issue=5&rft.spage=796&rft.epage=807&rft.pages=796-807&rft.issn=1340-6868&rft.eissn=1880-4233&rft_id=info:doi/10.1007/s12282-022-01357-x&rft_dat=%3Cgale_proqu%3EA714262896%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2654298045&rft_id=info:pmid/35460066&rft_galeid=A714262896&rfr_iscdi=true |